Which company in the pharmaceutical industry is growing? The list is out

"Pharmaceutical Network Industry Dynamics" recently, DataBao newly released the A-share pharmaceutical industry's top 50 list, combing the industry's potential stocks.
data show that more than five institutions forecast net profit and next year and 2022 net profit growth is positive of pharmaceutical stocks, more than 70 stocks next year and 2022 net profit growth average of more than 20%.
, the pharmaceutical companies at the top of the list are American Health, and the agency has unanimously forecast that the company's net profit will grow more than eight times next year, by more than 32% in 2022, with an average growth rate of more than four times.
's main business is the medical industry, accounting for about 99.52% of revenue, respectively.
It is understood that in recent years, the United States health business mainly around the healthy people's consumption upgrade, medical scene fee upgrade and life science and technology innovation and upgrading three aspects, with the promotion of the big health strategy, the company's growth is also highlighted.
in the health care, the company is accelerating the sinking of third- and fourth-tier cities.
2018, the United States has more than 600 medical and medical centers in more than 200 core cities across the country, providing professional health services to nearly 30 million people, and is expected to reach 100 million in 2024.
Xingqi eye medicine, East A gum followed closely behind, Kantai Bio, Boray Pharmaceuticals, Chengdu pilot, Steyri and other stocks in the next two years, the average net profit growth rate of more than 50%.
It is learned that ophthalmology concept stocks Xingqi eye medicine recently by the agency research heat continues to heat up, September 22 to obtain 230 institutions pile up research, the company said in the survey, cyclosporine after the listing of clinical results by experts, the future dry eye market is very large, the current 0.05% of cyclosporine has entered the medical insurance preliminary examination directory.
East A gum is a favorite of many investors ten times the stock, is a rare consumer stocks and pharmaceutical stocks features.
, the company's losses are expected to narrow and fundamentals are recovering.
addition, the A gum industry still maintains a certain scale of growth.
2017-2022, the industry will maintain a 15% growth rate, and by 2022 the market size of A gum will reach 71.7 billion yuan, according to the China Business Industry Research Institute.
and East A gum as the industry's leading players, long-term monopoly position.
, according to the Forward-Looking Industry Research Institute, in 2019, the size of the East A gum market accounted for 61.30% of the overall market size of the A gum industry.
its main competitors with a market share of about 16.53 per cent and a focus on the lower end of the market.
and East A gum is focused on the mid- to high-end market, the industry is expected to become more obvious competitive advantage.
addition, Hengrui Pharmaceuticals, ranked 50th, forecast net profit growth of 27.71 percent next year and 26.03 percent, respectively, with an average of 26.87 percent.
pharmaceutical industry has high investment, high risk, high returns and other characteristics, therefore, pharmaceutical companies need to go longer, often need higher investment in research and development and strong risk resistance.
It is understood that Hengrui Pharmaceuticals in 2019 research and development investment reached 3.9 billion yuan, in the past three years, the annual research and development expenditure of more than 1 billion yuan, ranked first in the A-share pharmaceutical unit research and development expenditure, and research and development efforts show a growing trend year by year.
understood that under the high-intensity investment, Hengrui Pharmaceuticals reached every 1-2 years there is a benign development trend of innovative drugs on the market.
end of 2019, the company's products cover anti-tumor drugs, surgical anesthesia drugs, special infusions, contrast agents, cardiovascular drugs and many other fields, forming a relatively complete product layout.
with the development trend of innovative drugs, the industry believes that the high growth of Hengrui Medicine has a greater guarantee.